Markets:

Overview

News

Currencies

International

Treasuries

Humacyte, Inc. - Common Stock (NQ:HUMA)

0.7030 +0.0130 (+1.88%)

Streaming Delayed Price Updated: 3:10 PM EDT, Jul 14, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 09, 2024

Via Benzinga

10 Best Stock Traders In Congress In 2023 (Spoiler: Nancy Pelosi Is Back On The List) ↗

January 02, 2024

A new report highlights the 10 members of Congress who profited the most from the stock market in 2023.

Via Benzinga

Tommy Tuberville Lost On Tesla Trade, Could Win Big On US Steel Trade: A Look At The Congress Trades Raising Eyebrows ↗

December 19, 2023

Senator Tommy Tuberville has been actively trading United State Steel stock and options ahead of a proposed buyout.

Via Benzinga

Humacyte: Q3 Earnings Insights ↗

November 09, 2023

Via Benzinga

Humacyte's Earnings: A Preview ↗

November 08, 2023

Via Benzinga

Humacyte Earnings Preview ↗

August 11, 2023

Via Benzinga

Recap: Humacyte Q1 Earnings ↗

May 12, 2023

Via Benzinga

Humacyte to Present at the Piper Sandler 35th Annual Healthcare Conference

November 24, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte Announces Two Presentations at the VEITHsymposium® of Positive Clinical Results of the Human Acellular Vessel™ (HAV™) in the Treatment of Vascular Trauma

November 17, 2023

From Humacyte, Inc

Via GlobeNewswire

Sidoti Events, LLC’s Virtual November Micro-Cap Conference

November 14, 2023

Via ACCESSWIRE

Humacyte Third Quarter 2023 Financial Results and Business Update

November 09, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Present Third Quarter Financial Results and Provide Corporate Update on November 9, 2023

November 02, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte Publishes Preclinical Results Showing Human Acellular Vessel™ (HAV™) Patency as Modified Blalock–Taussig–Thomas Shunt in Juvenile Primate Model

October 16, 2023

-Outcomes exhibit potential of HAV for palliative treatment of congenital heart disease-

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Present at the Cantor Global Healthcare Conference

September 21, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Host In-Person KOL Event at the New York EDITION on September 20, 2023

September 18, 2023

From Humacyte, Inc

Via GlobeNewswire

Regenerative Medicine Firm Humacyte's Bioengineered Tissue Shows Promise In Trauma Injuries ↗

September 12, 2023

Humacyte Inc (NASDAQ: HUMA) released topline results from its V005 Phase 2/3 trial of the Human Acellular Vessel (HAV) in vascular trauma repair, showing that the HAV had higher rates of patency and...

Via Benzinga

Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗

September 12, 2023

Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday.

Via Benzinga

Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

September 12, 2023

Gainers Tenon Medical, Inc. (NASDAQ: TNON) shares climbed 63.5% to $0.2351 after the company announced it has withdrawn its proposed public offering of shares of its common stock.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

September 12, 2023

It's time to start the day off with a breakdown of the biggest pre-market stock movers worth watching on Tuesday morning!

Via InvestorPlace

Humacyte Announces Positive Top Line Results from Phase 2/3 Trial of Human Acellular Vessel™ (HAV™) in Treatment of Patients with Vascular Trauma

September 12, 2023

From Humacyte, Inc

Via GlobeNewswire

Humacyte to Announce Top Line Data from Phase 2/3 V005 Trial in Vascular Trauma Evaluating its Human Acellular Vessel™ (HAV™) Tuesday, September 12, 2023 at 8:00 AM ET

September 11, 2023

Virtual Webinar to Include Key Opinion Leader Perspectives on the Potential of the HAV in Vascular Trauma Repair

From Humacyte, Inc

Via GlobeNewswire

Results From Mayo Clinic Clinical Study of Humacyte’s Human Acellular Vessel™ (HAV™) in Treatment of Patients with Chronic Limb Ischemia Presented at Midwestern Vascular Conference

September 11, 2023

-Researchers concluded that in the clinical study the HAV was a safe, resilient, and effective conduit for arterial bypass and limb salvage-

From Humacyte, Inc

Via GlobeNewswire

Senator's Perfect Timing? Russian War-Linked Biotech Buy Raises Eyebrows Amid Trading Ban Debate ↗

August 16, 2023

The public's scrutiny of Congress members trading stocks and options has intensified as websites and social media increasingly broadcast the disclosed data.

Via Benzinga

Paysafe, Taylor Devices, SomaLogic And Other Big Stocks Moving Higher On Tuesday ↗

August 15, 2023

U.S. stocks traded lower, with the Dow Jones falling around 300 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Intraday Session ↗

August 14, 2023

Via Benzinga

Humacyte Second Quarter 2023 Financial Results and Business Update

August 14, 2023

From Humacyte, Inc

Via GlobeNewswire

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023 ↗

June 22, 2023

Via Benzinga

Earnings Scheduled For May 12, 2023 ↗

May 12, 2023

Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.